|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|